Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia


Published in:
Haematologica

DOI:
10.3324/haematol.2009.016766

Link to publication

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia

Wendy Deenik,1 Jeroen J.W.M. Janssen,2 Bronno van der Holt,1 Gregor E.G. Verhoef,2 Willem M. Smit,4 Marie José Kersten,5 Simon M.G.J. Daenen,6 Leo F. Verdonck,7 Augustin Ferrant,8 Anton V.M.B. Schattenberg,9 Pieter Sonneveld,1 Marinus van Marwijk Kooy,7 Shulamit Wittebol,10 Roelof Wijermans,11 Pierre W. Wijermans,11 H. Berna Beverloo,7 Bob Löwenberg,2 Peter J.M. Valk,4 Gert J. Ossenkoppele,2 and Jan J. Cornelissen1

1Erasmus University Medical Center, Rotterdam, The Netherlands; 2VU Medical Center, Amsterdam, The Netherlands; 3University Hospital Gasthuisberg, Leuven, Belgium; 4Medical Spectrum Twente, Enschede, The Netherlands; 5Academic Medical Center, Amsterdam, The Netherlands; 6University Medical Center Groningen, Groningen, The Netherlands; 7Isala Clinic, Sophia, Zwolle, The Netherlands; 8University Hospital St-Luc, Brussels, Belgium; 9University Medical Center Nijmegen, Nijmegen, The Netherlands; 10Meander Medical Center, Amersfoort, The Netherlands; 11Leiden University Medical Center, Leiden, The Netherlands, and 12Haga Hospital, The Hague, The Netherlands

ABSTRACT

Background
In order to improve the molecular response rate and prevent resistance to treatment, combination therapy with different dosages of imatinib and cytarabine was studied in newly diagnosed patients with chronic myeloid leukemia in the HOVON-51 study.

Design and Methods
Having reported feasibility previously, we hereby report the efficacy of escalated imatinib (200 mg, 400 mg, 600 mg or 800 mg) in combination with two cycles of intravenous cytarabine (200 mg/m² or 1000 mg/m² days 1 to 7) in 162 patients with chronic myeloid leukemia.

Results
With a median follow-up of 55 months, the 5-year cumulative incidences of complete cytogenetic response, major molecular response, and complete molecular response were 89%, 71%, and 53%, respectively. A higher Sokal risk score was inversely associated with complete cytogenetic response (hazard ratio of 0.63; 95% confidence interval, 0.50-0.79, P<0.001). A higher dose of imatinib and a higher dose of cytarabine were associated with increased complete molecular response with hazard ratios of 1.60 (95% confidence interval, 0.96-2.68, P=0.07) and 1.66 (95% confidence interval, 1.02-2.72, P=0.04), respectively. Progression-free survival and overall survival rates at 5 years were 92% and 96%, respectively. Achieving a major molecular response at 1 year was associated with complete absence of progression and a probability of achieving a complete molecular response of 89%.

Conclusions
The addition of intravenous cytarabine to imatinib as upfront therapy for patients with chronic myeloid leukemia is associated with a high rate of complete molecular responses (Clinicaltrials.Gov Identifier: NCT00028847).

Key words: imatinib, cytarabine, escalated therapy, combination therapy, chronic myeloid leukemia.


©2010 Ferrata Storti Foundation. This is an open-access paper.
Introduction

The introduction of imatinib, a specific kinase inhibitor of the BCR-ABL protein, has dramatically changed prospects for patients with chronic myeloid leukemia (CML). Most patients with newly diagnosed chronic phase CML nowadays achieve a complete cytogenetic response, which subsequently predicts for relatively long survival. Moreover, patients achieving a major molecular response do even better, as not a single patient who attained such a response at 18 months had progressed at 5 years. The recently presented 7-year follow-up data of the International Randomized Study of Interferon and STI571 (IRIS) confirmed durability of cytogenetic responses and a low rate of progression. However, the estimated 5-year event-free survival was 85%, and an estimated another 16% of patients discontinued imatinib for various reasons within the first 5 years. Comparable results were observed in a recent large single center study, indicating that although the majority of patients enter a stable cytogenetic remission, more than one third of patients may still be in need of alternative therapy.

Patients needing second-line therapy include patients who do not tolerate imatinib and patients acquiring resistance. Primary or acquired resistance against imatinib is currently defined at hematologic, cytogenetic, and also molecular levels. It may be caused by different mechanisms, including point mutations in the BCR-ABL kinase domain, overexpression of BCR-ABL, additional chromosomal abnormalities in the Philadelphia (Ph)-positive clone, and a relative insensitivity of quiescent leukemia stem cells to imatinib. Prevention of resistance and improving the cytogenetic and molecular response rates may be achieved by different approaches, including dose escalation of imatinib, second-generation tyrosine kinase inhibitors, or combination therapy. Several combinations have been explored in vitro and also in early clinical studies. Among the combinations of imatinib and cytostatic drugs, the combination of cytarabine and imatinib was found to result in a synergistic effect, especially at higher concentrations of either drug. Based on these findings, the HOVON cooperative study group set out to explore the clinical feasibility and efficacy of the imatinib plus cytarabine combination, applying a step-wise dose-increase of either drug. Recently, feasibility results of that combination were reported. Here, the efficacy of the combination of imatinib and intravenous cytarabine is reported with emphasis on the rate and duration of molecular responses as well as their major determinants.

Design and Methods

The HOVON-51 was a multicenter study designed to investigate the feasibility and efficacy of escalated imatinib in combination with intravenous cytarabine in patients with early chronic phase CML. Inclusion criteria included: age between 18 and 65 years, presence of the Ph chromosome or BCR-ABL rearrangement, adequate organ function, registration within 6 months of diagnosis, and no previous treatment except for hydroxyurea. The ethics committees of all participating centers approved the study and informed consent was obtained from all patients in accordance with the Declaration of Helsinki. Patients were recruited from August 2001 to November 2005.

Study design and treatment

The design of the study has been described recently. In brief, patients were assigned to one of seven predefined, successive dose levels. Dose levels were open for inclusion only when the preceding dose level had met the criteria of acceptable toxicity and safety. First, a pre-phase of imatinib (400 mg) monotherapy was given to all patients for 2 to 3 weeks. This was followed by combination therapy of two cycles of intravenous cytarabine (200 mg/m² or 1000 mg/m² days 1 to 7) with imatinib (200 mg, 400 mg, 600 mg or 800 mg once daily). Imatinib (400 mg, 600 mg or 800 mg) maintenance therapy was continued after the second cycle until disease progression, intolerance of treatment, or eligibility for allogeneic stem cell transplantation (SCT), whichever occurred first. Dose adjustments during imatinib maintenance therapy were made in the case of non-hematologic toxicity of Common Toxicity Criteria (CTC) grade 2 or higher as reported before, and as described in detail at www.hovon.nl.

Definition of end-points

The definition of molecular response was adapted in order to be compatible with the international scale. A laboratory-specific conversion factor to the international scale has been acquired via EUTOS for CML, which promotes quality controlled molecular monitoring using standardized real-time quantitative polymerase chain reaction (RT-PCR) technologies and establishment of an international definition of major molecular response (http://www.eutos.org/). A complete molecular response was defined as no residual BCR-ABL transcripts by RT-PCR (in duplicate), corresponding to a greater than 4.5 log-reduction of BCR-ABL copies. Only BCR-ABL values resulting from assaying with a level of sensitivity of at least 0.01% in duplicate were considered appropriate. If cytogenetic results were not available during follow-up, RT-PCR measurement of BCR-ABL was used as a surrogate for complete cytogenetic response, with BCR-ABL values below 1% being considered as indicating a complete cytogenetic response. Molecular response was centrally assessed at the Erasmus University Medical Center in Rotterdam using RT-PCR on peripheral blood and/or bone marrow. Molecular analysis was done at baseline, after cycles 1 and 2, at 6 months, and at least every 3 to 6 months thereafter. All patients who failed to achieve a major molecular response at 1 year were evaluated for point mutations in the ABL kinase domain, and the investigation was repeated during follow-up as long as patients failed to achieve a major molecular response. Patients who lost their initial response or progressed during follow-up were also evaluated for mutations. BCR-ABL mutation analyses were performed as previously described.

Cumulative incidences of response are expressed as the time from registration to complete hematologic response, major cytogenetic response, complete cytogenetic response, major molecular response, and complete molecular response. Loss of complete hematologic response was defined as a white blood cell count (WBC) greater than 20×10^9/L, or progression to advanced phase CML; loss of major cytogenetic response as an increase of Ph-positive metaphases by at least 50% points to 35% or more Ph-positive metaphases; loss of complete cytogenetic response by the detection of one or more Ph-positive metaphases, loss of major molecular response as a 0.5 log increase of BCR-ABL to a BCR-ABL level greater than 0.1%; and loss of complete molecular response as renewed detection of BCR-ABL transcript levels. In the case of loss of hematologic, cytogenetic or molecular responses, confirmation by a subsequent evaluation at least 1 month later was required. Progression was defined as the development of accelerated phase or blast crisis CML, whichever came first. Failure of imatinib treatment was defined as progression (to advanced phase CML), loss of complete hematologic response, loss of major cytogenetic response, or an increasing WBC (defined as doubling of the WBC to greater than 20×10^9/L on two occasions at least 1 month apart in a patient who had never attained a complete hematologic response despite receiving maximally tolerated doses of therapy).

Progression-free survival was defined as the time from registration
until progression or death, whichever came first. Failure-free survival was defined as the time from registration until failure on imatinib treatment or death, whichever came first. Of note, primary hematologic resistance is not included in the definition of failure-free survival due to cytopenias associated with combination treatment, which precludes an early evaluation of hematologic response. Event-free survival was defined as the time from registration until failure on imatinib treatment, discontinuation of imatinib treatment, going off protocol treatment for any reason, or death, whichever occurred first. Overall survival was calculated as the time from registration until death of any cause. Patients still alive at the date of last contact were then censored.

Statistical methods

The cumulative incidences of complete hematologic response, major cytogenetic response, complete cytogenetic response, major molecular response and complete molecular response were calculated using competing risk analysis. Competing risks were disease progression, discontinuation of treatment before achieving response, or death without previous response. As an allogeneic SCT was allowed as off protocol treatment if no cytogenetic response was acquired within 12 months or according to the physician’s preference, patients who underwent this treatment were censored at the date of the transplant. Progression-free, event-free, failure-free and overall survival rates were estimated by the Kaplan-Meier method, and 95% confidence intervals (CI) were determined. Patients who underwent allogeneic SCT were censored at the date of transplantation. Time to response and survival end-points were illustrated by Kaplan-Meier curves until 5 years.24 In our trial, patients had been assigned to receive standard- or intermediate-dose cytarabine, as well as low/standard-dose (200 and 400 mg) or high-dose (600 mg and 800 mg) imatinib. Univariate and multivariate Cox regression analyses,25 without and with interaction terms, were performed to evaluate the effect of higher dose levels and the impact of the Sokal risk score and Euro score on clinical outcome. Hazard ratios (HR) with 95% CI were determined. All reported P values are two-sided, and a significance level of α=0.05 was used.

Results

The patients’ characteristics are presented in Table 1. The median age at diagnosis was 47 years (range, 19-65 years); patients were fairly evenly distributed among the three Sokal risk categories. One hundred and sixty-two patients received a first cycle of combination therapy and 140 patients (86%) also received a second cycle of combination therapy. One hundred and fifty-seven patients (97%) started with imatinib maintenance therapy. The current analysis is based on data collected up to December 18, 2008, resulting in a median follow-up of 55 months (range, 10-84 months). Currently, 112 patients (69%) are still on protocol treatment, and 50 patients went off protocol treatment for various reasons including progression to accelerated phase or blast crisis in 7 patients, loss of hematologic or cytogenetic response in 7 patients, no complete hematologic response at 6 months in 2 patients, toxicity in 12 patients, proceeding to allogeneic SCT in 18 patients and other reasons in 4 patients. Second-line therapy included allogeneic SCT from either a matched unrelated donor in 18 patients, nilotinib or dasatinib in 14 patients, chemotherapy in 7 patients, and other treatment modalities in 7 patients.

Hematologic, cytogenetic, and molecular responses

The patients’ responses are presented in Table 2, and Figures 1A-C and 2A-B. One hundred and fifty-four patients achieved a complete hematologic response, 146 patients a major cytogenetic response, and 135 patients a complete cytogenetic response, based on cytogenetic evaluation in 130 patients and quantitative PCR in 5 patients. The median time to a complete cytogenetic response was

<table>
<thead>
<tr>
<th>Table 1. Baseline characteristics of all patients.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characteristic</td>
</tr>
<tr>
<td>Age at diagnosis, years</td>
</tr>
<tr>
<td>Sex, n. (%)</td>
</tr>
<tr>
<td>Sokal risk group, n. (%)</td>
</tr>
<tr>
<td>intermediate (0.8-1.2)</td>
</tr>
<tr>
<td>high (&gt;1.2)</td>
</tr>
<tr>
<td>unknown</td>
</tr>
<tr>
<td>Euro score, n. (%)</td>
</tr>
<tr>
<td>low ≤780</td>
</tr>
<tr>
<td>intermediate (&gt;780-1480)</td>
</tr>
<tr>
<td>high (&gt;1480)</td>
</tr>
<tr>
<td>unknown</td>
</tr>
<tr>
<td>Dose of imatinib, n. (%)</td>
</tr>
<tr>
<td>low/standard-dose (200 mg and 400 mg)</td>
</tr>
<tr>
<td>high-dose (600 mg and 800 mg)</td>
</tr>
<tr>
<td>Dose of cytarabine, n. (%)</td>
</tr>
<tr>
<td>standard-dose (200 mg/m²)</td>
</tr>
<tr>
<td>intermediate-dose (1000 mg/m²)</td>
</tr>
</tbody>
</table>

Percentages may not sum up to 100% due to rounding.
approximately 4.5 months. In total, 107 patients achieved a major molecular response, and 78 patients developed a complete molecular response on protocol treatment. In addition, we performed nested PCR in 51 of the 78 patients negative by real-time PCR, corresponding to a greater than 4.5-log reduction of BCR-ABL copies. All but nine of these patients were also negative by nested PCR. The median time to major molecular response was 11 months and the median time to complete molecular response was approximately 22 months. With a median follow-up of 55 months, 9 patients lost their complete hematologic response, 16 patients lost their previously established major cytogenetic response and 17 patients lost their complete cytogenetic response. Of all 107 patients with a major molecular response, 6 patients lost that response, and loss of complete molecular response was observed in 10 patients (Table 2). At 5 years, the cumulative incidences of a complete cytogenetic response, major molecular response, and complete molecular response were, respectively, 89%, 71%, and 53% (Figure 1A-C). Of note, 89% of the patients who achieved a major molecular response at 1 year subsequently developed a complete molecular response. Furthermore, none of the 107 patients with a major molecular response subsequently progressed to advanced phase CML, while 4 out of 135 patients with a complete cytogenetic response and 5 out of 27 patients who failed to achieve a complete cytogenetic response progressed to advanced phase CML. Among the 108 patients with a complete cytogenetic response at 1 year, 91 (88%) subsequently obtained a major molecular response and 71 patients (69%) ultimately developed a complete molecular response. In contrast, among 41 patients continuing protocol treatment, but who failed to achieve a complete cytogenetic response at 1 year, 27 patients (66%) subsequently developed a complete cytogenetic response at later time points (Figure 1A), 15 patients (37%) attained a major molecular response, and only 6 patients (15%) ultimately developed a complete molecular response.

There were significant differences in the rates of major

Figure 1. Cumulative incidences of (A) complete cytogenetic response (CCR), (B) major molecular response (MMR), and (C) complete molecular response (CMR).

Figure 2. Cumulative incidences of (A) complete molecular response by dose of imatinib (HR = 1.60; 95% CI, 0.96–2.68, \( P = 0.07 \)) and (B) complete molecular response by dose of cytarabine (HR=1.66; 95% CI, 1.02–2.72, \( P = 0.04 \)).
and complete cytogenetic responses among patients according to Sokal risk and Euro scores in univariate analysis. A higher Sokal risk score remained adversely associated with major and complete cytogenetic responses (HR=0.63; 95% CI, 0.50-0.79, P<0.001) (Table 3) in multivariate analysis. At 1 year the cumulative incidences of a complete cytogenetic response was 76% in patients with a low Sokal score, 74% in patients with an intermediate Sokal score, and 40% in patients with a high Sokal score. However, at 5 years these differences in response rates were less pronounced, being 89%, 93%, and 81%, in low, intermediate, and high-risk patients, respectively. The latter higher response rate in high-risk patients at 5 years appeared primarily due to a slower developing response rate. A higher Sokal score was also inversely associated with major molecular response (HR = 0.74; 95% CI, 0.58-0.96, P=0.02) (Table 3), but not with complete molecular response. In contrast, the dose of imatinib and the dose of cytarabine were not associated with cytogenetic response, but a higher dose of imatinib appeared to be associated with a better major and complete molecular response rate (HR = 1.66; 95% CI, 1.02-2.72, P=0.04) (Table 3, Figure 2B).

Progression-free, overall, failure-free, and event-free survival

After a median follow-up of 55 months, nine patients had developed advanced phase CML and three patients had died resulting in a 5-year progression-free survival rate of 92% (95% CI, 85%-95%) (Figure 3A). The estimated annual rate of progression was 5.0% in the first year, 0.7% in the second year, 0.8% in the third year, 2.2% in the fourth year, and 0% in the fifth year. Due to the limited number of events, prognostic factors for progression-free survival were not evaluated. In total, six patients died, resulting in an overall survival rate at 5 years of 96% (95% CI, 92%-98%). The causes of death of these six patients were blast crisis CML in three patients, excessive toxicity in two patients and an unrelated cause in one patient. Recipients of an allogeneic stem cell graft were censored at the time of transplantation for the latter analysis in concordance with earlier reports and to facilitate comparison.25 Twenty-seven patients ultimately underwent allogeneic SCT as second- or third-line therapy, predominantly because of primary (8 patients) or secondary resistance (9 patients). Other reasons for performing allogeneic SCT included intolerance of imatinib (3 patients) and physicians’ preference (7 patients). Twelve out of these 27 patients died due to either non-relapse mortality (n=11) or progressive disease (n=1). Survival without censoring the allogeneic disease (n=1).

Survival without censoring the allogeneic disease (n=1). Survival without censoring the allogeneic disease (n=1).

Table 3. Results of the multivariate analysis.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Major cytogenetic response</th>
<th>Complete cytogenetic response</th>
<th>Major molecular response</th>
<th>Complete molecular response</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR (95% CI)</td>
<td>P value</td>
<td>HR (95% CI)</td>
<td>P value</td>
</tr>
<tr>
<td>Dose of cytarabine</td>
<td>1.08 (0.75-1.57)</td>
<td>0.66</td>
<td>1.02 (0.69-1.51)</td>
<td>0.91</td>
</tr>
<tr>
<td>Dose of imatinib</td>
<td>1.07 (0.74-1.55)</td>
<td>0.73</td>
<td>1.38 (0.93-2.04)</td>
<td>0.11</td>
</tr>
<tr>
<td>Sokal risk score</td>
<td>0.56 (0.45-0.70)</td>
<td>&lt;0.001</td>
<td>0.63 (0.50-0.79)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Figure 3. (A) Event-free survival (EFS), failure-free survival (FFS), progression-free survival (PFS), and overall survival (OS). (B) Landmark analysis of failure-free survival by major molecular response (MMR) at 1 year.
free survival. A landmark analysis of the 103 patients who had achieved a complete cytogenetic response at 1 year revealed a superior estimated 5-year failure-free survival of 97% as compared to 77% in 41 patients without a complete cytogenetic response at 1 year (P<0.001) (data not shown). Moreover, the 5-year failure-free survival rate of 61 patients who rapidly achieved a major molecular response by 12 months was higher than that of the 83 patients who had failed to attain a such a response by 1 year (100% versus 86%; P=0.002) (Figure 3B).

Event-free survival was also assessed. Overall, 50 events were noted, resulting in a 5-year event-free survival rate of 69% (95% CI, 61%-76%) (Figure 3A). Higher Sokal risk and Euro scores were associated with worse event-free survival in univariate analysis. A higher Sokal risk score remained adversely associated with event-free survival (HR = 1.55; 95% CI, 1.08-2.22, P=0.02), when adjusted for dose of cytarabine and imatinib.

**Point mutations in the BCR-ABL kinase domain**

Patients failing to achieve a major molecular response at 1 year, and at subsequent evaluation time points thereafter were evaluated for point mutations within the BCR-ABL kinase domain. In addition, patients with primary or secondary hematologic or cytogenetic resistance and all patients who, at any time, progressed to advanced phase CML were evaluated for mutations. In total, 153 samples were evaluated for point mutations in the kinase domain, showing a cumulative incidence of mutations of 10% at 5 years. In total, 14 different mutations were detected in 15 patients, including 2 patients with a T315I mutation. Nine of these 15 patients with a mutation subsequently lost their response, and 3 patients progressed to advanced phase CML.

**Tolerance of protocol treatment**

Adverse events and side effects during the phase of combination therapy have already been reported in detail. During maintenance, the most frequent adverse events of CTC grade 2 or more included constitutional symptoms (54%) and gastrointestinal complaints (53%); toxicity of CTC grade 3 or 4 occurred infrequently. Both the incidence and severity of these side effects were essentially similar to the those of the side effects that can be observed in patients receiving monotherapy with imatinib as reported before. Combination therapy and maintenance were well tolerated as illustrated by the fact that only 9% of patients discontinued treatment because of side effects (n=15), which represent all discontinuations including the toxic deaths, an event-free survival of 69%, and a total number of 112 patients still continuing protocol treatment.

**Discussion**

Imatinib treatment is associated with high rates of complete cytogenetic and major molecular responses in patients with first chronic phase CML, although complete molecular responses occur significantly less frequently and the majority of patients continue to harbor minimal residual disease, necessitating prolonged treatment with imatinib. With the ultimate aim of improving the complete molecular response rate, the HOVON study group set out to explore combination therapy of escalated doses of imatinib and cytarabine. With a median follow-up of 55 months, the long-term efficacy of this combination therapy is presented here. The most important findings of our study include a relatively high complete molecular response rate, a low incidence of primary cytogenetic and molecular resistance, and a relatively high number of patients still continuing protocol treatment, while maintaining their remission.

The cumulative incidence of a complete molecular response was 53% at 5 years. A higher dose of imatinib monotherapy may already be associated with faster and better responses, although different results were observed in distinct risk-categories of patients. In addition, an association has been observed between plasma trough levels and outcome. A modest dose-dependent effect of imatinib was also apparent in our study (Table 2, Figure 3A). Furthermore, the earlier observed in vitro synergistic or additive effect of cytarabine seems to have been mirrored here clinically. An additive effect of cytarabine is further supported by the significant dose-dependent effect of cytarabine observed in our study. Moreover, up to the latest follow-up, none of the patients receiving the higher dose of cytarabine has developed progressive disease. A high complete molecular response rate of approximately 50% was reported earlier by Branford et al. These results cannot be compared directly with those from the present study, as we estimated cumulative incidences with competing risk-analysis. However, the median time to complete molecular response differed markedly, being 18 months in the present study and approximately 4 years in the Australian study. Recently, Cortes et al. reported results obtained with 800 mg imatinib in newly diagnosed patients. Approximately 50% of patients evaluable at 18 months after the start of treatment had obtained a complete molecular response, which comes close to what was observed in the present study, but these favorable results were obtained in a relatively good-risk group in that 70% of the patients had a low-risk Sokal score. The issue of an additive effect of cytarabine does, therefore, remain open, but may be settled by a prospective randomized trial that is currently underway. Two other cooperative groups explored the combination of cytarabine and imatinib. A French cooperative group demonstrated the feasibility of imatinib and low-dose cytarabine, but their long-term results are not yet available. An Australian cooperative group developed a protocol including addition of cytarabine for patients failing to obtain a sufficient response 3 months after dose escalation of imatinib. However, only a minority of patients actually received the combination, which precludes any definite conclusion as regards the additive value of cytarabine in their study.

By inducing a high complete molecular response rate, combination therapy may prevent primary resistance at the various levels, and it may also prevent secondary resistance in patients relapsing from an earlier established response. Primary cytogenetic resistance, defined as failure to achieve a complete cytogenetic response at 18 months, was observed in 36 patients (22%) in our study. Nineteen out of these 36 patients (53%) who failed to achieve a complete cytogenetic response by 18 months had a high-risk Sokal score. While a 22% failure rate may be somewhat lower than that which can be observed following imatinib only (approximately 50% in the Hammersmith study), primary cytogenetic resistance is still of concern and combination therapy only partially
prevented cytogenetic resistance. It indicates that a subset of high-risk patients is still in need of a more efficient therapeutic approach. Furthermore, additional parameters apart from those incorporated in the Sokal and Euro scores may be needed to more accurately identify the patients at highest risk of primary cytogenetic resistance. New diagnostic techniques such as gene expression profiling and single nucleotide polymorphisms may possibly add to the well-established risk scores. Secondary resistance percentages were rather low and progression-free survival estimated at 92% at 5 years. As outlined by de Lavallade et al., another important outcome estimate is the 5-year probability of achieving and maintaining a major cytogenetic response, while continuing imatinib. It was 63% for patients with early chronic phase CML receiving a standard-dose of imatinib in the Hammersmith series of patients. For comparison, 69% of the patients in the present study maintained at least an earlier established major cytogenetic response and were still on imatinib according to protocol. Apart from an encouraging efficacy of combination therapy, this high percentage of patients continuing protocol treatment also illustrates that combination therapy was rather well tolerated.

Our results, as well as those by several others, clearly suggest that patients with a more pronounced response, such as a major molecular response, benefit in terms of a lower risk of disease progression and prolonged progression-free survival. Therefore, aiming for a major molecular response has been advocated as an important treatment goal by several investigators. Is a further improvement up to the level of a complete molecular response of additional benefit? Recent preliminary reports have suggested that a subset of patients in continued complete molecular response may potentially be cured, as was suggested by absence of molecular relapse following cessation of imatinib maintenance initially described by Rousselot et al. A more recent follow-up and inclusion of a total of 50 patients essentially showed the same picture with approximately 50% of patients maintaining PCR-negativity after cessation of imatinib. A similar observation was made in Australia, with a relatively high failure-free survival rate, but longer follow-up may be needed to determine definitely to what extent patients may be cured.

In conclusion, following earlier in vitro findings, our clinical results may mirror the contributing effect of cytarabine to that of imatinib in patients with first chronic phase CML. The additive value of cytarabine in first chronic phase CML seems to be better eradication of residual disease, as reflected by a relatively high rate of complete molecular responses. While cytogenetic resistance may partially be prevented, a subset of high-risk patients still represents a category of patients for whom better therapeutic approaches are needed. The ultimate advantage of an increased complete molecular response rate should be assessed in future studies, including well-monitored trials evaluating the cessation of imatinib in patients with a long-lasting complete molecular response.

**Authorship and Disclosures**

WD, JJWMJ, BH, GEG, BL, GJO, and JJC were responsible for the design of the present analysis, actual evaluation, and writing the paper; all authors were responsible for the design of the HOVON study, treatment of patients, critical review of the paper, suggestions for additional analysis, and finalizing the writing of the paper. FS, GJO, and JJC have received consulting fees from Novartis Oncology. No other potential conflicts of interests relevant to this article were reported.

**References**

of nilotinib (formerly AMN107) in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-ABL). Blood. 2008;112: Abstract 446.


